marked.bio

Company

ORIC Pharmaceuticals

2 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

ORIC-114 2amivantamab 1

Trials

2 of 2 trials shown

  1. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

    Recruiting Phase 1/2 ORIC Pharmaceuticals Started 2022Primary completion 2026-09 NCT05315700

    ORIC-114carboplatinpemetrexed

    …d or metastatic solid tumor with a documented EGFR or HER2 exon 20 insertion mutation or atypical EGFR mutation as determined by any nucleic acid-based diagnostic testing method, or HER2 amplification/…

    EGFR exon 19 deletion / L858REGFR exon 20 insertionHER2 (ERBB2) activating mutationSolid Tumors

  2. ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

    Recruiting Phase 1 ORIC Pharmaceuticals Started 2025Primary completion 2026-12 NCT06816992

    ORIC-114amivantamab FDA EU

    Histologically or cytologically confirmed metastatic NSCLC with a documented EGFR exon 20 insertion mutation as determined locally by any nucleic acid-based diagnostic testing method

    EGFR exon 20 insertionSolid Tumors, EGFR Exon 20 Insertion Mutations, NSCLC, EGFR-mutated NSCLC